Literature DB >> 3582418

Effect of cisapride and metoclopramide on digoxin bioavailability.

W Kirch, H D Janisch, S R Santos, U Duhrsen, P Dylewicz, E E Ohnhaus.   

Abstract

Pharmacokinetics of digoxin were investigated in six healthy volunteers following one week of digoxin monotherapy 0.25 mg b.i.d., and during coadministration of metoclopramide 10 mg t.i.d. or cisapride 10 mg t.i.d.. Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14). Metoclopramide prolonged the time required to reach the peak concentration of digoxin from 2 hr to 2.7 hr (p = 0.17), cisapride did not. Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06). It is concluded that the gastrointestinal absorption of digoxin is reduced by both substances. Monitoring of the patient's clinical status should be recommended when metoclopramide and cisapride are coadministered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3582418     DOI: 10.1007/BF03189108

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  3 in total

1.  Altered absorption of digoxin in patients given propantheline and metoclopramide.

Authors:  V Manninen; A Apajalahti; J Melin; M Karesoja
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

2.  Effect of metoclopramide on digoxin absorption from tablets and capsules.

Authors:  B F Johnson; J A Bustrack; D R Urbach; J H Hull; R Marwaha
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

3.  The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.

Authors:  C G Regårdh; P Lundborg; B A Persson
Journal:  Biopharm Drug Dispos       Date:  1981 Jan-Mar       Impact factor: 1.627

  3 in total
  10 in total

1.  The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease.

Authors:  A Taylor; A Beerahee; D Citerone; M Davy; K Fitzpatrick; A Lopez-Gil; F Stocchi
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

Authors:  J A Zix; H F Geerdes-Fenge; M Rau; J Vöckler; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Authors:  V H Deneer; L Lie-A-Huen; J H Kingma; J H Proost; J C Kelder; J R Brouwers
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 5.  Cisapride. Drug interactions of clinical significance.

Authors:  T A Bedford; D J Rowbotham
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 6.  Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders.

Authors:  R W McCallum; C Prakash; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 7.  Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Authors:  J M Greiff; D Rowbotham
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 9.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 10.  Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.

Authors:  William L Hasler; Philip Schoenfeld
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.